MARKET WIREMoomoo • 23h ago
ABVC BioPharma(ABVC) Stock Options Chain | Quotes & NewsMoomoo report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
Why ABVC Stock slipped -1.99% Today — RQD Quant Desk Flash
$0.98 -1.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.97
ABVC BioPharma Inc. (ABVC) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $26.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ABVC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ABVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, ABVC BioPharma Inc. (NASDAQ: ABVC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.98 (-1.99% 1D, market cap $26.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABVC ranks #733 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ABVC compare to BCTX and CPHI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVC carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and CPHI (China Pharma Holdings Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -11.4%, cap $26.9M). Among the 5-stock peer group, ABVC leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ABVC?
▼
Per ABVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001173313), ABVC BioPharma Inc. generated $20.0M in revenue (+3829.3% YoY), -$7.9M in net income, and -$3.0M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.97 (-0.55%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABVC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY ABVC SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.98-5.1% Next Q
24
Q2 (-2Q)Grade E$0.93+12.9% Next Q
27
Q3 (-1Q)Grade E$1.05-6.7% Next Q
29
CurrentGrade E$0.98-9.2% Hist 90D α
32
Trajectory: E (24) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ABVC Turnaround Squeeze
While ABVC currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.00) and Max Pain ($1.03) forces dealer call-delta covering toward $3.21.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABVC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABVC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ABVC Stock slipped -1.99% Today — RQD Quant Desk Flash
ABVC BioPharma Inc. (ABVC) slipped -1.99% to $0.98, trading at 11% of its 52-week range ($0.71 – $3.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($0.71 – $3.06) with RSI-14 at 48.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.98 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ABVC Headlines & Catalysts
RISK WATCHYahoo! Finance Canada • 1d ago
WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 MillionYahoo! Finance Canada report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Form 8K ABVC Biopharma Inc For: 2 November By Investing.comInvesting.com UK report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com India • 1d ago
ABVC BioPharma raises $3.39 million via convertible notes By Investing.comInvesting.com India report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETipRanks • 1d ago
ABVC BioPharma Closes $4.11 Million Convertible Note FinancingTipRanks report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
RISK WATCHWallachBeth Capital LLC/ • 1d ago
/C O R R E C T I O NWallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), has closed a private placement of origina
RISK WATCHYahoo Finance • 1d ago
ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 MillionSILICON VALLEY, CA - November 2, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), today announced the closing of a private placement of original issue discount senior convertible promi
CATALYSTYahoo Finance • 133d ago
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC ShareholdersSILICON VALLEY, CA - June 23, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics and commercial ingre
MARKET WIREYahoo Finance • 244d ago
ABVC BioPharma Reports 2025 Form 10-KTotal Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model SILICON VALLEY, CA - March 3, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) today announced the filing of its A
MARKET WIREYahoo Finance • 252d ago
ABVC BioPharma Provides Corporate and Structural UpdateSILICON VALLEY, CA - February 24, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics and commercial i
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABVC)
- ✓Walkthrough of ABVC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABVC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.67%⚡ TESTING RESISTANCE
2026-11-03O $1.04H $1.04L $0.98C $0.98VOL 20.2K
RES: $1.07SUP: $0.94SMA50: $1.00SMA200: $1.25
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ABVC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +3829.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ABVC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ABVC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABVC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABVC)
Health Care Rank #733 of 1015
⚔️ BCTX vs ABVC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ABVC vs. BCTX, CPHI, BYSI, CELU)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, ABVC BioPharma Inc. (ABVC) ranks #733 by composite RQD confidence (32/100, grade E) and #809 by equity capitalization ($26.7M). Within this direct 5-issuer industry benchmark cohort, ABVC leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ABVC at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABVC
ACTIVE
ABVC BioPharma Inc. | E | 32/100 | — | — | -35.0% | -1.99% | $26.7M | Benchmark Subject |
| BCTX BriaCell Therapeutics Corp. | D- | 40/100 | — | — | — | +1.65% | $26.5M | /bctx-vs-abvc → |
| CPHI China Pharma Holdings Inc. | D- | 35/100 | — | -3.2% | -11.4% | -2.98% | $26.9M | /cphi-vs-abvc → |
| BYSI BeyondSpring Inc. | D- | 37/100 | — | — | -35.0% | +25.18% | $26.5M | /bysi-vs-abvc → |
| CELU Celularity Inc. (Class A) | E | 26/100 | — | 24.4% | -35.0% | +0.30% | $26.0M | /celu-vs-abvc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001173313 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), ABVC BioPharma Inc. (ABVC) reported GAAP revenue of $20.0M (+3829.3% vs. FY2024 revenue of $509.6K , and +13036.2% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of -$3.0M, and free cash flow of -$3.0M (-65.1% YoY). On the balance sheet, ABVC closed FY2025 with $21.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $20.0M | -$7.9M | -$3.0M | -$3.0M | $21.1M | — |
| FY2024 (FY) | 2024-12-31 | $509.6K | -$4.9M | -$1.8M | -$1.8M | $7.5M | — |
| FY2023 (FY) | 2023-12-31 | $152.4K | -$7.8M | -$4.2M | -$4.2M | — | — |
3. ABVC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ABVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, ABVC BioPharma Inc. (NASDAQ: ABVC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.98 (-1.99% 1D, market cap $26.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABVC ranks #733 in composite RQD confidence.
How does ABVC compare to BCTX and CPHI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVC carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and CPHI (China Pharma Holdings Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -11.4%, cap $26.9M). Among the 5-stock peer group, ABVC leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ABVC?
Per ABVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001173313), ABVC BioPharma Inc. generated $20.0M in revenue (+3829.3% YoY), -$7.9M in net income, and -$3.0M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ABVC trading relative to its 50-day, 200-day, and 52-week technical levels?
ABVC last traded at $0.98 (-1.99% on volume of 30,178 shares), positioning the stock -2.00% below its 50-day simple moving average ($1.00) and -21.60% below its 200-day simple moving average ($1.25). Across its 52-week range of $0.71 to $3.06, ABVC sits at the 11.5% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).
ROARABLE RATING BRIEF • RQD 32/100 (E)
✓ SEC XBRL & RQD VERIFIED
ABVC — ABVC BioPharma Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
ABVC BioPharma Inc. (ABVC) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.98 (-1.99% 1D, market capitalization $26.7M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -10.76%.
- Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
ABVC BioPharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is listed on NASDAQ.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ABVC BioPharma Inc. (ABVC) reported $20.0M in annual revenue (up from $509.6K in FY2024, +3829.3% YoY) and -$7.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($152.4K revenue, -$7.8M net income) through FY2025, ABVC scaled operating cash flow to -$3.0M and free cash flow to -$3.0M, backed by $21.1M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.76% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.71 – $3.06 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ABVC carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can ABVC sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $20.0M and free cash flow of -$3.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is ABVC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ABVC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for ABVC BioPharma Inc. (ABVC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Moomoo • 23h ago
ABVC BioPharma(ABVC) Stock Options Chain | Quotes & News Moomoo report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo! Finance Canada • 1d ago
WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million Yahoo! Finance Canada report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Form 8K ABVC Biopharma Inc For: 2 November By Investing.com Investing.com UK report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com India • 1d ago
ABVC BioPharma raises $3.39 million via convertible notes By Investing.com Investing.com India report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TipRanks • 1d ago
ABVC BioPharma Closes $4.11 Million Convertible Note Financing TipRanks report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH WallachBeth Capital LLC/ • 1d ago
/C O R R E C T I O N WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), has closed a private placement of origina
🔴 RISK WATCH Yahoo Finance • 1d ago
ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million SILICON VALLEY, CA - November 2, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), today announced the closing of a private placement of original issue discount senior convertible promi
🟢 CATALYST Yahoo Finance • 133d ago
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders SILICON VALLEY, CA - June 23, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics and commercial ingre
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ABVC Bull vs. Bear Conversation Board — What's Your Call at $0.98?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABVC 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $1.16 (+16.0%)
📌 Pinned Debate The balance-sheet pillar scores 10 of 20, with Altman Z at 2.5 and Debt/Equity at 0.5, the strongest reading in the RQD rating.
Picked up a starter position in ABVC in my $100K Virtual Cash book at $1.00. The balance-sheet pillar scores 10 of 20, with Altman Z at 2.5 and Debt/Equity at 0.5, the strongest reading in the RQD rating.. Trading inside a $0.71–$3.06 52-week range with -10.76% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
RetailWhale_TX 🐂 BULL
Both sides have a point here — ABVC's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $0.86 (-14.0%)
Spot @ $1.00 Operating and net income are negative in every reported period, with FY 2025 net loss of -$7.9M against cash of $0.7M and an RQD score
Careful chasing ABVC at $1.00. Operating and net income are negative in every reported period, with FY 2025 net loss of -$7.9M against cash of $0.7M and an RQD score of 32.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.86 on multiple compression.